Canadian flagCanadian fulfilment · Free shipping $199+For laboratory research only
My account →Peptide Points →About Peptide Place →

Compound research profile

Tesamorelin Research Profile

Published October 28, 2026 · Updated November 11, 2026

Editorial cover for Tesamorelin Research Profile
Editorial illustration · read the original sources for evidence.

Tesamorelin is a growth hormone-releasing hormone analogue, often shortened to GHRH analogue. It is commonly discussed for visceral fat and body composition. Visceral fat is the fat around internal organs, which is different from fat under the skin.

Growth hormone and visceral-fat research

An analogue is a compound designed to resemble another biological signal. Tesamorelin relates to the signal that stimulates growth hormone release. This explains why it is discussed alongside ipamorelin, even though the receptor routes differ. Visceral-fat measurements should also be distinguished from total body weight and changes in muscle.

Reading the evidence

Falutz and colleagues studied tesamorelin in people with HIV and abdominal fat accumulation. That is a specific human research setting with a defined population and study formulation. It provides context for the visceral-fat discussion, rather than a general result for every body-composition goal or for this catalogue vial.

Tesamorelin vs ipamorelin vs MOTS-c

Tesamorelin acts through the GHRH pathway; ipamorelin through the ghrelin receptor. MOTS-c has a mitochondrial signalling background. These mechanisms make a more useful comparison than a shared fat-loss label. Read the human population or experimental model alongside the endpoint before comparing results.

Read the full comparison.

From research to product information

This profile explains the compound. The Tesamorelin product page lists current sizes, prices, specifications and linked batch records. Keep those product facts separate from findings about a different study material.

Original source

Read the original paper on PubMed

Keep learning

How to read peptide research · How to read a COA

Related reading: CJC-1295 No DAC vs Tesamorelin

Keep the clinical setting attached to the finding

Population, formulation and outcome matter when interpreting tesamorelin research. Review the clinical-evidence checklist and translate unfamiliar study terms before applying a conclusion to another question.

Explore this topic further

Tesamorelin in Canada

Reading the evidence

Visceral-fat endpoints in their population

The cited tesamorelin trial concerns a defined HIV-associated abdominal-fat context. Visceral adipose tissue, subcutaneous fat and total body weight should not be substituted for one another. The study formulation and product documentation are separate records.

MaterialWhat exactly was studied?
ModelWhich cells, tissue or population?
EndpointWhat did the source measure?

Follow this topic

The Peptide Place Insider

Your first order.
15% better.
Get 15% off
your first order.

Your welcome code, orders and Peptide Points. One free account.

Join Insider emails and create your free Peptide Place account. Unsubscribe anytime. Adults 19+.

Privacy · Offer terms · Already joined? Sign in